The diagnosis gap in pediatric hearing loss: Why one-size-fits-all protocols fall short

Pediatric hearing loss is not one diagnosis. Clinicians know this, but for infants who do not pass hearing screening, many care pathways still treat them according to a single workflow with a single destination. That approach misses etiologies, delays targeted counseling, and can lock families into device decisions before the biology is clear.

Most infants enter the system through Early Hearing Detection and Intervention (EHDI).^[] The 1-3-6 benchmark remains the backbone: Screen by 1 month, diagnose by 3 months, and start intervention by 6 months.

Many programs now push 1-2-3 when feasible. Those timelines matter because test conditions are easier early on, and earlier access to language changes outcomes.

The Joint Committee on Infant Hearing (JCIH) FAQ document stresses completing audiologic diagnosis no later than 2 to 3 months of age when possible. This is partly practical, since natural sleep auditory brainstem response (ABR) testing is easier in younger infants.^[]

But the bigger issue is its specificity.

How etiology shapes early counseling, escalation, and planning

Two infants can have the same ABR pattern and end up needing different counseling, different escalation, and different long-term planning. Distinctions that affect these decisions, as noted by the JCIH,^[] include:

• Conductive vs sensorineural loss

• Progressive vs stable loss

• Syndromic vs nonsyndromic risk

• Auditory neuropathy spectrum disorder (ANSD) vs cochlear hair-cell pathology

• Anatomic etiologies (cochlear nerve deficiency, inner ear malformations)

• Genetic auditory synaptopathies where hair cells function but synaptic transmission fails

Those distinctions shape how you talk to parents in the first weeks after diagnosis. They also shape how you choose confirmatory tests. 

A child with suspected ANSD needs more than a “refer” label. Families deserve clarity about what the test pattern means clinically, how speech perception might track with thresholds, and why hearing aids and cochlear implants perform differently across etiologies.

The limits of standard testing

One of the best examples of why the “one-protocol” approach fails is OTOF-related hearing loss. A type called DFNB9, caused by OTOF variants, often presents as congenital severe-to-profound hearing loss with features of auditory synaptopathy. Investigational gene therapy for these patients has yielded positive results.^[]

This subgroup of patients behaves differently than those with classic outer-hair-cell damage, however, and the counseling needs to reflect that. Lawrence Lustig, MD, one of the investigators in the trial, commented that traditional audiograms do not tell the full story of functional hearing, and therein lies a core counseling challenge.^[]

Dr. Wei elaborated on what general pediatricians can do differently when they get a newborn screen referral, recommending that they be sure to “refer patients/families to a pediatric otolaryngologist and the pediatric audiologists who work with them to provide team-based care.”

Pediatricians need to understand that “delay in diagnosis will result in delay in amplification, with subsequent delay in language and even cognitive development.”

So what does a more modern clinical approach look like, beyond the one-size-fits-all model? 

What to evaluate early—and why timing matters

Start with an etiology workup earlier in the process than in common pathways, and consider the following:

• Genetics. For bilateral congenital sensorineural hearing loss,  genetic testing often changes the next step, even when imaging is normal.

• CMV testing in the newborn window when applicable.

• Imaging based on phenotype and implant planning, but not as the default first-line answer.

• Neurologic and syndromic review guided by exam and family history.

CMV testing is particularly important. Jeremy Woods, MD, board-certified in pediatrics, medical genetics and genomics, states, “CMV testing has the greatest impact when it occurs early enough to guide confirmatory evaluation and longitudinal planning.”

Treat “cochlear implant candidate” as a time-sensitive decision, but not the only endpoint. Cochlear implants remain standard for many infants with profound congenital loss, and outcomes are often strong. But device timing intersects with emerging biology-based options in specific subtypes, including OTOF-mediated disease.

Counseling without overpromising

Experts recommend counseling families in simple terms, but avoid predicting a stable course until the cause is known. Build counseling around near-term decisions families must make.

Some causes are, in fact, often progressive (eg, congenital CMV, enlarged vestibular aqueduct/Pendred syndrome, mitochondrial causes), while others are frequently stable (eg, GJB2-related congenital hearing loss).

Importantly, even when audiogram thresholds remain stable, some children still have poor speech perception, especially in background noise, such as in auditory neuropathy spectrum disorder, where clarity can remain weak despite similar hearing thresholds over time.

Parents might not understand every detail in visit number one. But they should always be apprised regarding:

• What the testing shows today

• What the likely categories are

• What the next diagnostic step is and why

• What treatment decisions are time-dependent

• What to do this week, not “someday”